Exact Mass: 852.3708428000001
Exact Mass Matches: 852.3708428000001
Found 51 metabolites which its exact mass value is equals to given mass value 852.3708428000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Efepristin
C44H52N8O10 (852.3806212000001)
Pristinamycin IC
C44H52N8O10 (852.3806212000001)
Heme A
C49H56FeN4O6 (852.3549026000001)
Heme A differs from heme B in that a methyl side chain at ring position 8 is oxidized into a formyl group, and one of the vinyl side chains, at ring position 2, has been replaced by an isoprenoid chain. Like heme B, heme A is often attached to the apoprotein (cytochromes or globins) through a coordination bond between the heme iron and a conserved amino acid side-chain. An example of a metalloprotein that contains heme A is cytochrome c oxidase. Both the formyl group and the isoprenoid side chain are thought to play important roles in conservation of the energy of oxygen reduction by cytochrome c oxidase.(Wikipedia). Heme A differs from heme B in that a methyl side chain at ring position 8 is oxidized into a formyl group, and one of the vinyl side chains, at ring position 2, has been replaced by an isoprenoid chain. Like heme B, heme A is often attached to the apoprotein (cytochromes or globins) through a coordination bond between the heme iron and a conserved amino acid side-chain. An example of a metalloprotein that contains heme A is cytochrome c oxidase. Both the formyl group and the isoprenoid side chain are thought to play important roles in conservation of the energy of oxygen reduction by cytochrome c oxidase. [HMDB]
Trityl candesartan cilexetil
C52H48N6O6 (852.3635148000001)
PGP(i-14:0/PGJ2)
PGP(i-14:0/PGJ2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-14:0/PGJ2), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
PGP(PGJ2/i-14:0)
PGP(PGJ2/i-14:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGJ2/i-14:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
Viroisin, 2-(2-(methylsulfinyl)-L-tryptophan)-3-(4,5-dihydroxy-L-leucine)-4-L-alanine- 7
C36H52N8O14S (852.3323532000001)
3beta,21,24-trihydroxy-21,23;22,28;26,28-triepoxy-5alpha-stigmasta-8(9),14(15)-dien-3-O-beta-D-galactopyranosyl-(1->2)-beta-D-(6-O-acetyl)glucopyranoside
14beta-hydroxy-19beta-oxobufa-4,20,22-trienolide-3beta-O-{alpha-L-rhamnopyranosyl-[(1?4)-beta-D-glucopyranosyl]-(1?3)-alpha-L-rhamnopyranoside}|urginin C
3 9-bis(2 4-dicumylphenoxy)-2 4 8 10-te&
C53H58O6P2 (852.3708428000001)
N-[(3S,9Z,15S,21Z,27S,33Z)-15,27-diacetamido-7,19,31-trihydroxy-10,22,34-trimethyl-2,8,14,20,26,32-hexaoxo-1,13,25-trioxa-7,19,31-triazacyclohexatriaconta-9,21,33-trien-3-yl]acetamide
(SP-4-2)[7-Ethenyl-17-formyl-12-[(4E,8E)-1-hydroxy-5,9,13-trimethyl-4,8,12-tetradecatrienyl]-3,8,13-trimethyl-21H,23H-porphine-2,18-dipropanoato(4-)-kappan21,kappan22,kappan23,kappan24]-ferrate(2-)
C49H56FeN4O6 (852.3549026000001)
triacetylfusarinine C
D006401 - Hematologic Agents > D006397 - Hematinics > D005290 - Ferric Compounds
N-[(9E,21Z,33Z)-15,27-diacetamido-7,19,31-trihydroxy-10,22,34-trimethyl-2,8,14,20,26,32-hexaoxo-1,13,25-trioxa-7,19,31-triazacyclohexatriaconta-9,21,33-trien-3-yl]acetamide
13,29-dimethyl (1r,3r,6r,14r,17r,19r,22r,30r)-9,10,25,26-tetramethoxy-4,20-dioxo-5,21-dioxa-13,29,36,42-tetraazaundecacyclo[20.10.6.6⁶,¹⁷.0¹,³⁶.0³,³⁰.0⁶,¹⁴.0⁷,¹².0¹⁴,¹⁹.0²²,³⁰.0²³,²⁸.0¹⁷,⁴²]tetratetraconta-7,9,11,23,25,27,33,39-octaene-13,29-dicarboxylate
n-[(1e)-11-[(13e,24z)-16,22-dihydroxy-10-methoxy-11,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1²,⁵.1⁶,⁹]hentriaconta-1(28),2(31),4,6(30),8,13,24,26(29)-octaen-20-yl]-4,10-dimethoxy-5,9-dimethyl-6-oxoundec-1-en-1-yl]-n-methylformamide
(5z,8z,13e)-12-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl butanoate
4-carboxy-4-{[2-({2-[(2-{[2-({3-carboxy-1,3-dihydroxy-2-[(1-hydroxyoctylidene)amino]propylidene}amino)-1,3-dihydroxybutylidene]amino}-1,3-dihydroxybutylidene)amino]-1-hydroxy-5-(hydroxyimino-oxo-λ⁵-azanylidene)pentylidene}amino)-1-hydroxyethylidene]amino}-n-(hydroxyimino)butanimine oxide
[(1r,3r,3as,3bs,5s,5ar,6r,7s,9as,9br,11ar)-1-[(2r,5z)-7-{[(2r,3r,4s,5r)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-5-isopropylhept-5-en-2-yl]-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
[(1r,3r,3as,3bs,5s,5ar,6r,7s,9as,9br,11ar)-1-[(2r,5e)-7-{[(2r,3r,4s,5r)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-5-isopropylhept-5-en-2-yl]-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
(4s,7s,13r,22r)-13-ethyl-2,5,8,11,14,20-hexahydroxy-4-(1h-indol-3-ylmethyl)-7-[(4-methoxy-2-methyl-1h-indol-3-yl)methyl]-18,22-dimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octaazabicyclo[21.2.1]hexacosa-1(25),2,5,8,11,14,20,23(26)-octaen-17-one
C42H48N10O8S (852.3377128000001)